Investing on the edge
Back to Top


Our core biotech investment thesis at Gravity Fund is that humanity’s ability to engineer biology will fundamentally transform how we diagnose, treat, and manage disease. Tools like computational biology, protein folding modeling, evolutionary biology engines, rationally designed nanomaterials, and CRISPR enable an expanding pool of entrepreneurs to simulate, analyze and engineer biology

I’m thrilled to announce the launch of Gravity Fund, a thesis driven early-stage Venture Capital firm, alongside my Co-Founder and Managing Partner, Adam Gruver. We’ll be investing in extraordinary entrepreneurs building bleeding edge technology on the brink of commercialization in four defined sectors: Consumer Marketplaces & Applications, Fintech & Crypto, Enterprise Software,